Diabetes Research and Clinical Practice
Volume 62, Issue 1 , Pages 1-8 , October 2003

Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells

  • Hye Kyung Hong

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • ,
  • Young Min Cho

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • ,
  • Kyung-Ho Park

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • ,
  • Choon-Taek Lee

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • ,
  • Hong Kyu Lee

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • The Institute of Endocrinology, Nutrition and Metabolism, Seoul National University Medical Research Center, Seoul, South Korea
    • ,
  • Kyong Soo Park

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea
    • The Institute of Endocrinology, Nutrition and Metabolism, Seoul National University Medical Research Center, Seoul, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82-2-760-1789; fax: +82-2-3676-8309

Received 22 January 2003 ,Revised 19 May 2003 ,Accepted 10 June 2003.

References 

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(1988):1595–1607 Banting lecture
  2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  3. Ross R. Atherosclerosis—an inflammatory disease. New Engl. J. Med. 1999;340:115–126
  4. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 2001;22:36–52
  5. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 2000;11:362–368
  6. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care. 2001;24:392–397
  7. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPAR-γ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311–1318
  8. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 1998;83:1097–1103
  9. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 1993;265:R726–R732
  10. Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, et al. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis. 1998;136:275–279
  11. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  12. Tontonoz P, Nagy L, Alverez JG, Thomazy VA, Evans RM. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–252
  13. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 1999;19:546–551
  14. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial cell function. Biochem. Biophys. Res. Commun. 1999;258:431–435
  15. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 1999;274:9116–9121
  16. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem. 1999;274:17042–17048
  17. de Dios ST, Hannan KM, Dilley RJ, Hill MA, Little PJ. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J. Diabetes Complications. 2001;15:120–127
  18. Gralinski MR, Rowse PE, Breider MA. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J. Cardiovasc. Pharmacol. 1998;31:909–913
  19. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications. 1998;12:181–186
  20. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentration of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000;49:633–639
  21. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, Fanghanel-Salmon G, Gallegos-Martinez J, Gomez-Diaz RA, et al. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism. 2002;51:44–51
  22. Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb. Haemost. 1989;62:723–728
  23. Schneider DJ, Absher PM, Ricci MA. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation. 1997;96:2868–2876
  24. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–867
  25. Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J. Clin. Endocrinol. Metab. 2000;85:1563–1568
  26. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2001;21:1846–1851
  27. Zhang J, Fu M, Zhao L, Chen YE. 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma. Biochem. Biophys. Res. Commun. 2002;298:128–132
  28. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor-γ ligands inhibit Rb phosphorylation and G1→S transition in vascular smooth muscle cells. J. Biol. Chem. 2000;275:22435–22441
  29. Underwood PA, Bean PA, Cubeddu L. Human endothelial cells grow poorly on vitronectin: role of PAI-1. J. Cell Biochem. 2001;82:98–109
  30. Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, Carmeliet P, et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res. 2003;63:1500–1507
  31. Dart AM, Chin-Dusting JP. Lipids and the endothelium. Cardiovasc. Res. 1999;43:308–322
  32. Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch. Ophthalmol. 2001;119:709–717

PII: S0168-8227(03)00142-6

doi: 10.1016/S0168-8227(03)00142-6

Diabetes Research and Clinical Practice
Volume 62, Issue 1 , Pages 1-8 , October 2003

Article Tools

* Image Usage & Resolution